Hilary Nicholson

Hilary Nicholson is a Senior Scientist at Tango Therapeutics, a clinical-stage biotechnology company focused on developing precision medicine for cancer treatment. She holds a Ph.D. and has been actively involved in research related to cancer therapies, particularly in the context of synthetic lethality and tumor biology.

Professional Contributions

Nicholson has presented significant research findings at various scientific conferences. Notably, she is scheduled to present on the topic "LIG1 inactivation selectively inhibits growth of BRCA1 mutant cells in vitro and in vivo" at an upcoming event on April 8, 2024.1 Her work contributes to understanding how specific genetic alterations can be targeted for therapeutic benefit in cancer patients.

Research Focus

Her research primarily revolves around:

• Synthetic Lethality: Exploring how certain genetic mutations can be exploited to develop targeted therapies.
• Cancer Cell Biology: Investigating the mechanisms by which cancer cells evade treatment and identifying potential therapeutic targets.

Publications

Nicholson has co-authored several publications detailing her findings on inhibitors and their effects on cancer cells, including work on selective inhibitors for treating specific types of tumors.2

Overall, Hilary Nicholson's expertise and ongoing research efforts are integral to advancing the field of oncology and developing innovative treatment options for cancer patients.